Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Simcere Pharmaceutical Group Limited ( (HK:2096) ) has shared an update.
Simcere Pharmaceutical Group’s subsidiary Jiangsu Simcere Zaiming Pharmaceutical has signed an exclusive licensing agreement granting Ipsen global rights outside Greater China to develop, manufacture and commercialize SIM0613, a LRRC15-targeting antibody-drug conjugate for cancer. Under the deal, Simcere is eligible to receive up to US$1.06 billion in upfront, development, regulatory and commercial milestone payments, plus tiered royalties on future sales, positioning SIM0613 as a potentially important oncology asset in Simcere’s pipeline while expanding its international reach and validating its ADC platform through collaboration with a major global biopharmaceutical player.
The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page.
More about Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited is an innovation- and R&D-driven pharmaceutical company that has established a State Key Laboratory focused on neurology and oncology drug development. The company concentrates on therapeutic areas including neuroscience, oncology, autoimmune diseases and anti-infective treatments, with a forward-looking strategy targeting disease areas with significant future clinical needs, and it advances its pipeline through in-house research and strategic collaborations with innovative companies and research institutes.
Average Trading Volume: 8,446,958
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.03B
Learn more about 2096 stock on TipRanks’ Stock Analysis page.